Form 4: Axsome Therapeutics Director Mark E. Saad Executes Stock Options and Sells Shares Under 10b5-1 Plan

Director Mark E. Saad of Axsome Therapeutics exercised stock options and sold shares on September 11, 2024, according to a Form 4 filing with the SEC.

Summary

• Mark E. Saad, a director at Axsome Therapeutics, exercised stock options to acquire 11,016 shares of common stock at a price of $3.67 on September 11, 2024.
• The exercise was conducted prior to the options' expiration date later in September.
• Following the exercise, Saad sold 11,016 shares of common stock at a weighted average price of $91.31, with individual sale prices ranging from $90.25 to $92.90.
• These transactions were executed under a pre-approved 10b5-1 trading plan.
• After these transactions, Saad directly owns 10,002 shares and indirectly owns 300 shares.
• The indirectly held shares are held as custodian for his children's UTMA accounts.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it simply reports transactions. The director is selling shares, which could be seen as slightly negative, but it's under a pre-approved plan.

Positives

• The execution of stock options and subsequent sale of shares indicate that the director is realizing value from their equity compensation.

Industry Context

Form 4 filings are standard disclosures required by the SEC when corporate insiders, like directors and officers, trade their company's stock. These filings provide transparency into insider transactions and are closely watched by investors.

Stakeholder Impact

• Shareholders may be interested in the director's transactions as an indicator of their confidence in the company.
• The sale of shares could create slight downward pressure on the stock price in the short term.

Key Dates